Related references
Note: Only part of the references are listed.A Clinical-Stage Cysteine Protease Inhibitor blocks SARS-CoV-2 Infection of Human and Monkey Cells
Drake M. Mellott et al.
ACS CHEMICAL BIOLOGY (2021)
A Review of Small Molecule Inhibitors and Functional Probes of Human Cathepsin L
Dibyendu Dana et al.
MOLECULES (2020)
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
Markus Hoffmann et al.
CELL (2020)
Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 patients
Tianxiao Liu et al.
PHARMACOLOGY & THERAPEUTICS (2020)
CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells
Ke Wang et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)
The role of cysteine peptidases in coronavirus cell entry and replication: The therapeutic potential of cathepsin inhibitors
Anja Pislar et al.
PLOS PATHOGENS (2020)
Revealing the molecular mechanisms of proteolysis of SARS-CoV-2 Mpro by QM/MM computational methods
Katarzyna Swiderek et al.
CHEMICAL SCIENCE (2020)
Design of Gallinamide A Analogs as Potent Inhibitors of the Cysteine Proteases Human Cathepsin L and Trypanosoma cruzi Cruzain
Paul D. Boudreau et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Antiprotozoal and cysteine proteases inhibitory activity of dipeptidyl enoates
Santiago Royo et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2018)
Quantum mechanics/molecular mechanics studies of the mechanism of cysteine protease inhibition by peptidyl-2,3-epoxyketones
Kemel Arafet et al.
PHYSICAL CHEMISTRY CHEMICAL PHYSICS (2017)
Computational Study of the Catalytic Mechanism of the Cruzain Cysteine Protease
Kernel Arafet et al.
ACS CATALYSIS (2017)
Cathepsin L and B as Potential Markers for Liver Fibrosis: Insights From Patients and Experimental Models
Mansi Manchanda et al.
CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY (2017)
Dipeptidyl Nitroalkenes as Potent Reversible Inhibitors of Cysteine Proteases Rhodesain and Cruzain
Antonio Latorre et al.
ACS MEDICINAL CHEMISTRY LETTERS (2016)
Dipeptidyl Enoates As Potent Rhodesain Inhibitors That Display a Dual Mode of Action
Santiago Royo et al.
CHEMMEDCHEM (2015)
THE CATHEPSIN-L INHIBITOR CAA0225 PROTECTS AGAINST MYOCARDIAL ISCHAEMIA-REPERFUSION INJURY
W. He et al.
HEART (2015)
Binding Isotope Effects as a Tool for Distinguishing Hydrophobic and Hydrophilic Binding Sites of HIV-1 RT
Agnieszka Krzeminska et al.
JOURNAL OF PHYSICAL CHEMISTRY B (2015)
Development of a highly potent, selective, and cell-active Inhibitor of cysteine cathepsin L-A hybrid design approach
Dibyendu Dana et al.
CHEMICAL COMMUNICATIONS (2014)
Identification of new peptide amides as selective cathepsin L inhibitors: The first step towards selective irreversible inhibitors?
Ana Torkar et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2013)
PTRAJ and CPPTRAJ: Software for Processing and Analysis of Molecular Dynamics Trajectory Data
Daniel R. Roe et al.
JOURNAL OF CHEMICAL THEORY AND COMPUTATION (2013)
Role of Solvent on Nonenzymatic Peptide Bond Formation Mechanisms and Kinetic Isotope Effects
Katarzyna Swiderek et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2013)
Cysteine Cathepsins in the secretory vesicle produce active peptides: Cathepsin L generates peptide neurotransmitters and cathepsin B produces beta-amyloid of Alzheimer's disease
Vivian Hook et al.
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2012)
LigPlot+: Multiple Ligand-Protein Interaction Diagrams for Drug Discovery
Roman A. Laskowski et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2011)
PROPKA3: Consistent Treatment of Internal and Surface Residues in Empirical pKa Predictions
Mats H. M. Olsson et al.
JOURNAL OF CHEMICAL THEORY AND COMPUTATION (2011)
Proteomic Identification of Protease Cleavage Sites Characterizes Prime and Non-prime Specificity of Cysteine Cathepsins B, L, and S
Martin L. Biniossek et al.
JOURNAL OF PROTEOME RESEARCH (2011)
Structural basis for reversible and irreversible inhibition of human cathepsin L by their respective dipeptidyl glyoxal and diazomethylketone inhibitors
Rajesh T. Shenoy et al.
JOURNAL OF STRUCTURAL BIOLOGY (2011)
Novel Peptidyl Aryl Vinyl Sulfones as Highly Potent and Selective Inhibitors of Cathepsins L and B
Laura Mendieta et al.
CHEMMEDCHEM (2010)
PhI(OAc)2/KI-Mediated Reaction of Aryl Sulfinates with Alkenes, Alkynes, and α,β-Unsaturated Carbonyl Compounds: Synthesis of Vinyl Sulfones and β-Iodovinyl Sulfones
Praewpan Katrun et al.
EUROPEAN JOURNAL OF ORGANIC CHEMISTRY (2010)
Cathepsin L, target in cancer treatment?
Jacqueline M. Lankelma et al.
LIFE SCIENCES (2010)
Challenging a paradigm: Theoretical calculations of the protonation state of the Cys25-His159 catalytic diad in free papain
Michael Shokhen et al.
PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS (2009)
Ester bonds in prodrugs
Luke D. Lavis
ACS CHEMICAL BIOLOGY (2008)
Cysteine cathepsin proteases as pharmacological targets in cancer
Carmela Palermo et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2008)
The M06 suite of density functionals for main group thermochemistry, thermochemical kinetics, noncovalent interactions, excited states, and transition elements: two new functionals and systematic testing of four M06-class functionals and 12 other functionals
Yan Zhao et al.
THEORETICAL CHEMISTRY ACCOUNTS (2008)
Increased expression and activity of nuclear cathepsin L in cancer cells suggests a novel mechanism of cell transformation
Brigitte Goulet et al.
MOLECULAR CANCER RESEARCH (2007)
Proteolytic processing of dynamin by cytoplasmic cathepsin L is a mechanism for proteinuric kidney disease
Sanja Sever et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Automatic atom type and bond type perception in molecular mechanical calculations
Junmei Wang et al.
JOURNAL OF MOLECULAR GRAPHICS & MODELLING (2006)
Rational design of aziridine-containing cysteine protease inhibitors with improved potency: Studies on inhibition mechanism
Radim Vicik et al.
CHEMMEDCHEM (2006)
Scalable molecular dynamics with NAMD
JC Phillips et al.
JOURNAL OF COMPUTATIONAL CHEMISTRY (2005)
Cathepsin L is essential for onset of autoimmune diabetes in NOD mice
R Maehr et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis
JA Joyce et al.
CANCER CELL (2004)
Cathepsin L-deficient mice exhibit abnormal skin and bone development and show increased resistance to osteoporosis following ovariectomy
W Potts et al.
INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY (2004)
Senescence-initiated reversal of drug resistance: Specific role of cathepsin L
X Zheng et al.
CANCER RESEARCH (2004)
Development and testing of a general amber force field
JM Wang et al.
JOURNAL OF COMPUTATIONAL CHEMISTRY (2004)
A point-charge force field for molecular mechanics simulations of proteins based on condensed-phase quantum mechanical calculations
Y Duan et al.
JOURNAL OF COMPUTATIONAL CHEMISTRY (2003)
Impaired cathepsin L gene expression in skeletal muscle is associated with type 2 diabetes
XD Huang et al.
DIABETES (2003)
Cathepsin L in secretory vesicles functions as a prohormone-processing enzyme for production of the enkephalin peptide neurotransmitter
S Yasothornsrikul et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Lysosomal cysteine proteases (cathepsins): promising drug targets
D Turk et al.
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2003)
Human and parasitic papain-like cysteine proteases:: Their role in physiology and pathology and recent developments in inhibitor design
F Lecaille et al.
CHEMICAL REVIEWS (2002)
Fast, efficient generation of high-quality atomic charges. AM1-BCC model: II. Parameterization and validation
A Jakalian et al.
JOURNAL OF COMPUTATIONAL CHEMISTRY (2002)
Novel, nonpeptidic cyanamides as potent and reversible inhibitors of human cathepsins K and L
JP Falgueyret et al.
JOURNAL OF MEDICINAL CHEMISTRY (2001)
Share Paper
